Matthew Ferguson - Dec 2, 2022 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson
Stock symbol: ELUT
Transactions as of: Dec 2, 2022
Transactions value $: $126,400
Form type: 4
Date filed: 12/5/2022, 07:44 PM
Previous filing: Sep 12, 2022
Next filing: Mar 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELUT	Class A Common Stock	Purchase	$24.2K	+6K	+34.85%	$4.03	23.2K	Dec 2, 2022	Direct	F1
transaction	ELUT	Class A Common Stock	Purchase	$95K	+20K	+86.14%	$4.75	43.2K	Dec 5, 2022	Direct
transaction	ELUT	Class A Common Stock	Purchase	$7.22K	+2K	+4.63%	$3.61	45.2K	Dec 5, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.05. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.56 to $3.65. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.00 to $4.05. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.56 to $3.65. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.